Clarivate’s Epidemiology's coverage of Soft tissue sarcoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Soft tissue sarcoma for each country, as well as annualized case counts projected to the national population.
Clarivate’s Epidemiology's Soft tissue sarcoma will answer the following questions:
Of all people with Soft tissue sarcoma, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
Of all people diagnosed with Soft tissue sarcoma, how many in each country across the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Soft tissue sarcoma over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, Clarivate Epidemiology also provides at least ten years of forecast data for the following Soft tissue sarcoma subpopulations:
Total prevalent cases by diagnosis status.
Diagnosed prevalent cases by drug-treatment status.
Natasha Nahar, M.P.H.,Epidemiologist, Epidemiology. Ms. Nahar holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai and a bachelor’s degree in dental surgery from BVDU Dental College and Hospital in Sangli.
Narendra Parihar, B.D.S., M.P.H., Senior Manager, Epidemiology. Dr Parihar is a team lead at Clarivate Epidemiology. He specializes in modelling and forecasting epidemiology patient populations across multiple indications. His primary areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. His qualifications include a master’s degree in public health with specialization in health policy, economics, and finance from Tata Institute of Social Sciences Mumbai, and a bachelor’s degree in dental surgery from the Rajasthan University of Health Sciences.